-

Shareholder Alert: Robbins LLP Reminds Investors the Lead Plaintiff Deadline is Approaching for Gulfport Energy Corporation (GPOR) Class Action

SAN DIEGO & OKLAHOMA CITY, Okla.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Gulfport Energy Corporation (NASDAQ: GPOR) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between May 3, 2019 and February 27, 2020. Gulfport Energy engages in the exploration, development, acquisition, and production of natural gas, crude oil, and natural gas liquids.

If you suffered a loss as a result of Gulfport's misconduct, click here.

Gulfport Energy Corporation (GPOR) Discloses Material Weakness in Financial Reporting

On February 27, 2020, Gulfport disclosed that its previously issued financial statements for the three and nine months ended September 30, 2019, "should no longer be relied upon due to material misstatements." The Company further stated that as a consequence of these misstatements it determined "a material weakness in internal control over financial reporting existed as of September 30, 2019, and therefore the Company has concluded that its disclosure controls and procedures as of September 30, 2019 were not effective." On this news, Gulfport's stock price fell almost 9% to close at $0.82 per share.

If you purchased Gulfport Energy Corporation (GPOR) securities between May 3, 2019 and February 27, 2020, you have until May 18, 2020, to ask the court to be appointed lead plaintiff for the class.

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Wil...

Investor Notice: Robbins LLP Informs Investors of the Eos Energy Enterprises, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a n...
Back to Newsroom